Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

Table 5 Utility sensitivity analysis

	Utilities				Incremental effectiveness in gained QALYs	ICER in $/QALY
	Cabozantinib		BSC			German model	US model
	stable	prog	stable	prog		German model	US model
Base Case [20, 21, 23]	0.760	0.680	0.760	0.680	0.15	375,470	1,189,706
Base Case increased by findings of Abou-Alfa et al. [19]	0.852	0.680	0.760	0.680	0.20	266,479	844,359
Cabozantinib as first-line in advanced RCC [29]	0.817	0.777	0.817	0.777	0.15	362,825	1,149,640
Base case adjusted by AE caused disutilities^a [30, 31]	0.728	0.680	0.751	0.680	0.13	427,215	1,353,665
Base case with constantly decreasing utility after progression^b	0.760	0.680	0.760	0.680	0.14	387,439	1,227,631

prog progressive, BSC best supportive care, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio, AE Adverse event. ^a The detailed estimations are presented in the Additonal file 1. ^b Utilities decreased 0.005 per month for both groups

ISSN: 1471-230X